• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even with Weight Loss Medications

    12/5/24 8:30:00 AM ET
    $LFMD
    $MED
    Medical/Nursing Services
    Health Care
    Packaged Foods
    Consumer Staples
    Get the next $LFMD alert in real time by email

    While 8 out of 10 U.S. adults trying to lose weight are eager to reach their goal as soon as possible, they agree that weight loss is an ongoing process requiring consistent attention and effort*

    Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, today shared findings from a recent independent survey. Commissioned by Medifast and conducted by the third-party market research firm Talker Research, the goal of the survey was to better understand American perceptions of weight loss medications and their role in health journeys, while also identifying areas where further support is necessary.

    The survey of 2,000 nationally representative U.S. adults who are trying to lose weight revealed that while weight loss medications are seen as a viable tool, there is a clear understanding among respondents that medications are not a standalone solution. 65% of respondents believe that weight loss medications are more effective when used together with lifestyle changes, and 45% agreed that medications alone won't allow them to reach their long-term goals.

    Moreover, the survey found that even if weight loss medications were readily available, a majority of respondents would still commit to lifestyle changes to reach their goals. Specifically, 73% said they would commit to healthy eating, 72% would commit to regular exercise, and 55% would prioritize quality sleep.

    Other notable findings include:

    • More than half (58%) of respondents said they wished they had more support on their weight loss journeys.
    • 58% of respondents said they would be inclined to try a medically supported weight loss program if it offered personalized meal plans and a support group.

    "Weight loss is a journey that requires a holistic approach, including proper nutrition, adequate exercise, sufficient sleep, and a healthy mindset," said Dan Chard, chairman and chief executive officer of Medifast. "The survey results clearly point to a growing need and desire among U.S. adults for a more comprehensive, balanced approach to weight loss that complements or goes beyond just medication. It is evident that the majority of people trying to lose weight understand the importance of lifestyle changes and are looking for effective tools and support to help them in their efforts."

    Chard added, "With our habit-based and coach-guided lifestyle solution, OPTAVIA, Medifast is uniquely positioned to meet this clear consumer demand. We offer customized programs and the support of coaches who draw upon their own personal weight loss experience – two of the top tools respondents identified as crucial. Our coaches not only help people lose the weight, but also teach them how to keep it off. For more than 40 years, Medifast has committed to championing nutrition and lifestyle changes, aligning perfectly with the needs and wants of those striving to create a healthy lifestyle. As the market continues to grow, we remain dedicated to supporting individuals in achieving their health and wellness goals through a holistic approach that incorporates both lifestyle changes and, where clinically appropriate, weight loss medications."

    Studies have shown that use of FDA-approved GLP-1 medications together with a lifestyle modification program like OPTAVIA may help you achieve an average reduction in body weight of 15% (Wadden et al., 2021; Wilding et al., 2021). Medifast embraces this holistic strategy and leverages this data in its unique approach. The company offers personalized plans that incorporate both the use of appropriate medications and the support of experienced coaches who have personally navigated their own weight loss journeys to create a comprehensive framework for a healthy lifestyle.

    *This random double-opt-in survey of 2,000 people who are trying to lose weight was commissioned by Medifast between May 2, 2024, and May 8, 2024. It was conducted by market research company Talker Research, whose team members are members of the Market Research Society (MRS) and the European Society for Opinion and Marketing Research (ESOMAR).

    About Medifast®:

    Medifast (NYSE:MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, which provides people with a simple yet comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA's holistic solution includes lifestyle plans with clinically proven health benefits, scientifically developed products, and a framework for habit creation – all reinforced by independent coach support for customers on their weight loss journeys. Through its collaboration with national virtual primary care provider LifeMD® (NASDAQ:LFMD) and its affiliated medical group, the holistic solution now includes access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature™. Visit the OPTAVIA and Medifast websites for more information and follow @Medifast on X and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241204987167/en/

    Get the next $LFMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What percentage of survey respondents believe that weight loss medications are more effective when used with lifestyle changes?

      65% of respondents feel that weight loss medications are more effective when combined with lifestyle changes.

    • What lifestyle changes are respondents willing to commit to in their weight loss journeys?

      73% said they would commit to healthy eating, 72% to regular exercise, and 55% to prioritizing quality sleep.

    • What percentage of respondents wished they had more support while trying to lose weight?

      58% of respondents expressed a desire for more support on their weight loss journeys, indicating a significant demand for assistance.

    • What do the majority of respondents prefer in a medically supported weight loss program?

      58% of surveyed adults would be inclined to try a medically supported weight loss program that includes personalized meal plans and a support group.

    • How is Medifast responding to the survey findings regarding the approach needed for effective weight loss?

      Medifast, through its OPTA program, is positioned to address consumer needs for a holistic approach that includes medication and lifestyle changes.

    Recent Analyst Ratings for
    $LFMD
    $MED

    CompanyDatePrice TargetRatingAnalyst
    LifeMD Inc.
    $LFMD
    3/16/2026$8.00Neutral → Outperform
    Mizuho
    LifeMD Inc.
    $LFMD
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    LifeMD Inc.
    $LFMD
    12/10/2024$12.00Buy
    Lake Street
    LifeMD Inc.
    $LFMD
    12/4/2024$7.00Neutral
    Mizuho
    MEDIFAST INC
    $MED
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    LifeMD Inc.
    $LFMD
    8/23/2024$11.00Buy
    B. Riley Securities
    MEDIFAST INC
    $MED
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    LifeMD Inc.
    $LFMD
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $LFMD
    $MED
    SEC Filings

    View All

    SEC Form S-8 filed by LifeMD Inc.

    S-8 - LifeMD, Inc. (0000948320) (Filer)

    4/1/26 4:57:56 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC

    SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)

    3/27/26 10:32:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    3/20/26 8:35:54 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $LFMD
    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program

    NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings. The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable for

    3/31/26 8:45:41 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea

    3/24/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Medifast Announces Cooperation Agreement with Steamboat Capital

    Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders Medifast, Inc. (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company's 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the comp

    3/20/26 8:30:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $LFMD
    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pisano Christopher A

    4 - LifeMD, Inc. (0000948320) (Issuer)

    4/1/26 5:33:43 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Pisano Christopher A

    3 - LifeMD, Inc. (0000948320) (Issuer)

    4/1/26 5:32:25 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form 3 filed by new insider Kavthekar Atul

    3 - LifeMD, Inc. (0000948320) (Issuer)

    4/1/26 5:31:27 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $LFMD
    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    9/12/24 2:10:03 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    LifeMD upgraded by Mizuho with a new price target

    Mizuho upgraded LifeMD from Neutral to Outperform and set a new price target of $8.00

    3/16/26 8:33:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Lake Street initiated coverage on LifeMD with a new price target

    Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

    12/10/24 8:29:49 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    $MED
    Financials

    Live finance-specific insights

    View All

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on April 15, 2026, to holders of record at the close of business on April 3, 2026. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's hea

    3/24/26 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Report Fourth Quarter 2025 Financial Results on March 9

    NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on March 9, 2026, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Monday, March 9thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-343-5172International Dial-In:203-518-9856Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy ser

    2/23/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385

    2/17/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $LFMD
    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth. Marc Benathen, the Company's current CFO, is departing to pursue a new opportunity and will remain with LifeMD through March 31, 2026, to facilitate a smooth transition. "We are thrilled to welcome Atul to LifeMD," said Justin Schreiber, Chairman and CEO of LifeMD. "He is a versatile financial leader who has spent nearly three decades helping healthcare and technology companies scale, and h

    3/16/26 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    11/14/24 10:42:44 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples